53 results
8-K
EX-99.1
IMNM
Immunome, Inc.
9 Nov 23
Immunome Reports Third Quarter 2023 Financial Results
4:52pm
months ended September 30, 2023 was $4 million.
Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2023
8-K
EX-99.1
9wx2l3lse7g3zjchr
9 Aug 23
Immunome Reports Second Quarter 2023 Financial Results
8:27am
8-K
EX-99.1
ime9p3tr
5 May 23
Immunome Reports First Quarter 2023 Financial Results
8:19am
8-K
EX-99.1
irqf7qc
15 Nov 22
Other Events
4:17pm
8-K
EX-99.1
634qv
14 Nov 22
Immunome Reports Third Quarter 2022 Financial Results
9:06am
8-K
EX-99.1
n7i3h51mclj71a
5 Aug 22
Immunome Reports Second Quarter 2022 Financial Results
8:15am
8-K
EX-99.1
l2czb5 1xja
6 Jul 22
Other Events
5:15pm
8-K
EX-99.1
wqauw3lo
9 Jun 22
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
8:32am
8-K
EX-99.2
yf7xahy zb
9 Jun 22
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
8:32am
8-K
EX-99.1
zpzixv43c i5
19 May 22
Other Events
4:05pm
8-K
EX-99.1
ixzm8qv
12 May 22
Immunome Reports First Quarter 2022 Financial Results
8:34am